Abstract

Although musculoskeletal malignancies comprise a small group of cancers, a vast number of histological subtypes have been identified attesting to the heterogeneity of this class of tumours and the growing interest in their development. The mode of management for both bone and soft tissue sarcomas has been examined extensively and treatment guidelines have been proposed. Despite the intensive study and multidisciplinary treatment, a substantial proportion of tumours remain recalcitrant to therapy and recur locally and systemically. Improved methods of characterising these tumours may help in understanding their biology. Cytogenetic and molecular genetic techniques allow a subcellular dissection of these malignancies which may aid the identification of mechanisms that are important in tumorigenesis. Already candidate genes have been isolated which may play an important role in the deregulation of proliferation and or the adoption of a malignant phenotype, features which are fundamental in tumour development. By studying the molecular biology and cytogenetics of tumours it may be possible to improve diagnostic and prognostic accuracy thereby minimising over and under treatment.